ReviewTherapeutic advances in medical oncology2021
Current and future treatment options for
Review in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 61 citations in OpenAlex.
- Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open-Label Study.Pharmacology research & perspectives · 2026Article
- Molecular Analysis of EBUS-TBNA Samples for Nodal Staging in Non-Small Cell Lung Cancer.Cancers · 2026Review
- Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastaticThe Lancet regional health. Western Pacific · 2026Article
- Molecular Basis of c‑MET Inhibition by Approved Small Molecule Drugs: A Structural Perspective.ACS medicinal chemistry letters · 2026Review
- Review
- Management of advanced non-small cell lung cancer withJournal of thoracic disease · 2025Article
- Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.Clinical and translational medicine · 2025Article
- Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications.Cancers · 2025Review
- MOMENT registry: Patients with advanced non-small-cell lung cancer harboringJournal of comparative effectiveness research · 2025Observational
- Targeting c-Met in Cancer Therapy: Unravelling Structure-activity Relationships and Docking Insights for Enhanced Anticancer Drug Design.Current topics in medicinal chemistry · 2025Review
- Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma.Journal for immunotherapy of cancer · 2024Article
- SexAnnoDB, a knowledgebase of sex-specific regulations from multi-omics data of human cancers.Biology of sex differences · 2024Article
- Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer.Bioconjugate chemistry · 2024Article
- MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling.British journal of cancer · 2024Article
- Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.Future oncology (London, England) · 2024Article
- Savolitinib: A Promising Targeting Agent for Cancer.Cancers · 2023Review
- Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.International journal of molecular sciences · 2023Article
- Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Article
- The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been over three decades since the hepatocyte growth factor (HGF) ligand and its receptor MET proto-oncogene (MET) pathway was established as promoting cancer growth and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.